Fresenius Medical Care AG(FMS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, organic revenue increased by 8%, reported operating income grew by 31%, and reported net income rose by 82% [8][9] - Operating income margin improved to 11.3%, within the midterm target band of 10%-14% [9][12] - Earnings per share grew by 44%, reflecting earnings strength and the impact of the accelerated share buyback program [9][15] - Net leverage improved to 2.5x, down from 3.4x at the end of 2022 [12][14] Business Line Data and Key Metrics Changes - Care delivery segment revenue grew nearly 2% at constant currency, with organic revenue growth reaching almost 5% [19] - Value-based care segment saw organic revenue growth of 34%, driven by contract expansion and strong member months growth [10][19] - Care enablement revenue grew by 2% at constant currency, supported by volume growth and positive pricing developments [20] Market Data and Key Metrics Changes - Flat same-market treatment growth in the U.S. was observed, with expectations for a 2%+ recovery due to quality initiatives and the introduction of the 5008X machine [9][10] - The company anticipates continued stagnant growth in U.S. treatment volumes for 2026, with a gradual increase expected as mortality levels normalize [36][39] Company Strategy and Development Direction - The company introduced FME Reignite, a new 2030 strategy focusing on operational excellence, growth, and culture [4][5] - The FME25 transformation program exceeded its sustainable savings target, achieving EUR 804 million by year-end 2025 [6][13] - The company is strategically positioned for sustained value creation, targeting a compound annual growth rate of 3%-7% through 2028 [22][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing inflationary pressures and costs related to the launch of the new dialysis device in the U.S. as significant headwinds [27][31] - The outlook for 2026 is cautious, with expectations for broadly flat revenue growth and a focus on maintaining profitability while investing for future value creation [20][21] Other Important Information - The company generated EUR 2.7 billion in operating cash flow in 2025, demonstrating strong cash performance [14] - A dividend of EUR 1.49 is proposed for 2025, representing a 3% increase from 2024 [15] Q&A Session Questions and Answers Question: What is the biggest drag on the business currently? - Management indicated that ongoing inflationary pressures and costs related to the launch of the new dialysis device are significant factors [27][29] Question: Can you estimate the cost for the large-scale 5008X launch in the U.S.? - The estimated investment for the rollout of high-volume HDF and IT harmonization is between EUR 100 million and EUR 150 million, with about half allocated to HDF [33][34] Question: When do you expect to see a turnaround in U.S. treatment volumes? - Management projected flat volume growth for 2026 but expressed confidence in returning to a 2%+ growth once mortality levels normalize [36][39] Question: What is the perspective on the latest U.S. tariff changes? - Management noted that tariffs were immaterial in 2025 but expect some impact in 2026, monitoring developments closely [40][42] Question: In which locations in Germany is Fresenius Medical Care planning to invest? - Investments are planned in manufacturing plants in Schweinfurt and Sindelfingen, which are core producers of dialysis products [43][44]